SecurityABT / Abbott Laboratories
InstitutionIntegrated Investment Consultants, LLC
Shares14,620
Value $ 892,000
Related LSE:ABT / ABBOTT LABORATORIES
002819AC4 / Abbott Laboratories 6.15% Senior Notes 11/30/37
002824AW0 / Abbott Labs Fixed Rt 4.125% 05/27/2020
002824AY6 / Abbott Labs Fixed Rt Notes 5.3% 05/27/2040
002824AU4 / Abbott Labs Senior Notes 5.125% 04/01/19
002824AV2 / Abbott Labs Senior Notes 6% 04/01/39

Integrated Investment Consultants, LLC ownership in ABT / Abbott Laboratories

August 09, 2018 - Integrated Investment Consultants, LLC has filed a 13F-HR/A form disclosing ownership of 14,620 shares of Abbott Laboratories (NYSE:ABT) with total holdings valued at $892,000 USD as of June 30, 2018. Integrated Investment Consultants, LLC had filed a previous 13F-HR on April 12, 2018 disclosing 14,620 shares of Abbott Laboratories at a value of $876,000 USD. This represents a change in shares of 0.00 percent and a change in value of 1.83 percent during the quarter.

Other investors with positions similar to Integrated Investment Consultants, LLC include Hayek Kallen Investment Management, Stewardship Financial Advisors, Llc, Barrington Strategic Wealth Management Group LLC, Sowell Financial Services LLC, Confluence Investment Management Llc, and Amica Retiree Medical Trust.

Abbott Laboratories has declared a standard industrial code (sic) of 2834 which is the "Pharmaceutical Preparations" industry. Integrated Investment Consultants, LLC's top industries are "Motion Pictures and Film" (sic 78), "Furniture And Fixtures" (sic 25), and "Transportation By Air" (sic 45).

13F Filings

The Security, Class, and CUSIP columns in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names and cusips.

In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Effective
Date
Form Security Class CUSIP Share
Price
Shares Change
(%)
Value
(x1000)
Change
(%)
Cost
(x1000)
Profit
(x1000)
Return
(%)
2018-06-30 13F-HR/A-1 ABBOTT LABS COM Stock 002824100 60.47 14,620 0.00 892 1.83 0 16 1.83
2018-06-30 13F-HR ABBOTT LABS COM Stock 002824100 47,490 925
2018-03-31 13F-HR ABBOTT LABS COM Stock 002824100 56.65 14,620 0.95 876 13.32 8 95 12.32
2017-09-30 13F-HR ABBOTT LABS COM Stock 002824100 50.99 14,483 0.70 773 10.59 5 69 9.86
2017-06-30 13F-HR ABBOTT LABS COM Stock 002824100 46.51 14,383 0.00 699 9.39 0 60 9.39
2017-03-31 13F-HR ABBOTT LABS COM Stock 002824100 41.40 14,383 0.00 639 15.76 0 87 15.76
2016-12-31 13F-HR ABBOTT LABS COM Stock 002824100 39.66 14,383 0.00 552 -6.28 0 -37 -6.28
2016-09-30 13F-HR ABBOTT LABS COM Stock 002824100 40.13 14,383 25.66 589 30.89 118 21 4.70
2016-06-30 13F-HR ABBOTT LABS COM Stock 002824100 40.84 11,446 0.00 450 -7.22 0 -35 -7.22
2016-03-31 13F-HR ABBOTT LABS COM Stock 002824100 41.19 11,446 0.00 485 5.90 0 27 5.90
2015-12-31 13F-HR ABBOTT LABS COM 002824100 11,446 458

Related SEC Filings

ABT / Abbott Laboratories / VANGUARD GROUP INC - 3G/A (Passive Investment)

2018-02-08 sec.gov
abbottlaboratories.htm - Generated by SEC Publisher for SEC Filing SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   Schedule 13G   Under the Securities Exchange Act of 1934 (Amendment No.: 4 )*       Name of issuer:  Abbott Laboratories     Title of Class of Securities:  Common Stock     CUSIP Number:  002824100     Date of Event Which Requires Filing of this Statement: December 31, 2017   Check the appropriate box to designate the rule pursuant to which this Schedule is filed:   (X)

ABT / Abbott Laboratories / VANGUARD GROUP INC - 3G/A (Passive Investment)

2018-02-08 sec.gov
abbottlaboratories.htm - Generated by SEC Publisher for SEC Filing SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   Schedule 13G   Under the Securities Exchange Act of 1934 (Amendment No.: 4 )*       Name of issuer:  Abbott Laboratories     Title of Class of Securities:  Common Stock     CUSIP Number:  002824100     Date of Event Which Requires Filing of this Statement: December 31, 2017   Check the appropriate box to designate the rule pursuant to which this Schedule is filed:   (X)

ABT / Abbott Laboratories / BlackRock Inc. - 3G/A (Passive Investment)

2018-01-29 sec.gov
us0028241000_012418.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 6) ABBOTT LABORATORIES -------------------------------------------------------- (Name of Issuer) Common Stock -------------------------------------------------------- (Title of Class of Securities) 002824100 -------------------------------------------------------- (CUSIP Number) December 31, 2017 --------------------------------------------------

ABT / Abbott Laboratories / BlackRock Inc. - 3G/A (Passive Investment)

2018-01-29 sec.gov
us0028241000_012418.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 6) ABBOTT LABORATORIES -------------------------------------------------------- (Name of Issuer) Common Stock -------------------------------------------------------- (Title of Class of Securities) 002824100 -------------------------------------------------------- (CUSIP Number) December 31, 2017 --------------------------------------------------

Abbott Laboratories 3G/A (Passive Acquisition of More Than 5% of Shares)

2017-02-09 sec.gov
abbottlaboratories.htm - Generated by SEC Publisher for SEC Filing SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   Schedule 13G   Under the Securities Exchange Act of 1934 (Amendment No.: 3 )*       Name of issuer:  Abbott Laboratories     Title of Class of Securities:  Common Stock     CUSIP Number:  002824100     Date of Event Which Requires Filing of this Statement: December 31, 2016   Check the appropriate box to designate the rule pursuant to which this Schedule is filed:   (X)

Related News Stories

Abbott (ABT) Q3 Earnings Top Estimates, Guidance Narrowed

2h zacks
Abbott Laboratories (ABT - Free Report) reported third-quarter 2018 adjusted earnings from continuing operations of 75 cents per share, a penny ahead of the Zacks Consensus Estimate. The bottom line improved 13.6% year over year and remained at the upper end of the company’s guided range of 73-75 cents. Reported earnings from continuing operation in the quarter came in at 31 cents per share, a 3.1% drop year over year. (7-0)

Abbott Laboratories 2018 Q3 - Results - Earnings Call Slides

2h seekingalpha
The following slide deck was published by Abbott Laboratories in conjunction with their 2018 Q3 earnings call. (7-0)

ABT Stock Dips Following Q3 Earnings Results

4h investorplace
ABT stock was down on Wednesday after the company released its earnings report for the third quarter of 2018. (7-0)

7 Best ETFs to Buy Now for Defensive Stocks

2018-10-16 investorplace
With seasonal volatility, rising interest rates, uncertainty over a tariff war with China and fast-approaching mid-term elections all on the minds of investors, the best ETFs to buy now are those that invest in defensive areas of the market. (56-0)

Can Abbott's (ABT) Steady Overall Growth Aid Q3 Earnings?

2018-10-16 zacks
Abbott Laboratories (ABT - Free Report) is slated to report third-quarter 2018 results before the market opens on Oct 17. Last reported quarter, the company’s earnings per share exceeded the Zacks Consensus Estimate by 2.8%. Moreover, Abbott delivered positive surprises in the trailing four quarters, the average beat being 1.86%. (9-0)



CUSIP: 002824100